Dec 16, 2022
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj - Monoclonal Ab - Immunotherapy
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj DARATUMUMAB (DARZALEX) NIH National cancer institute - cancer.gov...
526
Dec 15, 2022
Patient Education: Lenalidomide - Immunomodulatory Agents - IMIDS
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS LENALIDOMIDE (REVLIMID) NIH National cancer institute...
535
Dec 10, 2022
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitors BORTEZOMIB (VELCADE) NIH National cancer institute -cancer.gov site info...
421
Dec 9, 2022
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor Carfilzomib NIH National cancer institute - cancer.gov site info This...
336
Dec 7, 2022
NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...
1,483
Dec 6, 2022
Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy
Patient Education: Ciltacabtagene Autoleucel https://www.carvykti.com Ciltacabtagene Autoleucel ( Carvykti) FDA approves ciltacabtagene...
254
Dec 6, 2022
Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy
Patient Education: Idecabtagene Vicleucel ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically...
454
Dec 6, 2022
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy ISATUXIMAB-IRFC (SARCLISA) NIH National cancer...
359
Dec 5, 2022
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS POMALIDOMIDE (POMALYST) NIH National cancer institute -...
294
Dec 4, 2022
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy ELOTUZUMAB (EMPLICITI) NIH National cancer...
283
Dec 4, 2022
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS THALIDOMIDE NIH National cancer institute - cancer.gov site...
235
Dec 3, 2022
Why is it important to become your own best advocate? HealthTree University Myeloma
Why is it important to become your own best advocate? Why is it important to become your own best myeloma advocate? HealthTree University...
209
Dec 3, 2022
What is a Myeloma Specialist Why do I Need one and How do I Find One? HealthTree University Myeloma
What is a Myeloma Specialist, Why do I Need one, and How do I Find One? HealthTree University Myeloma Dec 13, 2019 Learn more: HealthTree...
238
Dec 3, 2022
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor IXAZOMIB (NINLARO) NIH National cancer institute - cancer.gov site info This...
279
Dec 2, 2022
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor Selinexor (Xpovio) NIH National cancer institute - cancer.gov site info This page...
255
Dec 2, 2022
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
MagnetisMM-8 NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory...
276
Dec 1, 2022
Patient Education: Dexamethasaone (Decadron) and other Steroids
Patient Education: Dexamethasone and other steroids DEXAMETHASONE (DECADRON) NIH National cancer institute -cancer.gov site info on...
322
Dec 1, 2022
HealthTree Myeloma Round Table in Buffalo on September 17, 2022 / 09:00AM - 03:00PM EDT
Online and In Person Myeloma Round Table in Buffalo on September 17 SEP 17, 2022 / 09:00AM - 03:00PM EDT Myeloma Round Table in Buffalo...
48
Dec 1, 2022
NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
(GEM21menos65) (Isatuximab-VRD + ASCT) - (VRD extended + ASCT plus ERI) - (Isatuximab-VID + ASCT). ERI=Early Rescue Intervention...
324